

## News Release

### **Rosetta Genomics Appoints Ana C. Ward as Executive Vice President, Legal and Corporate Development**

**PHILADELPHIA and REHOVOT, Israel (February 29, 2016)** – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Ana C. Ward, Esq. as Executive Vice President, Legal and Corporate Development. Ms. Ward will join Rosetta Genomics as of March 1, 2016 and will work primarily from the Company's Lake Forest, California facility.

Ms. Ward brings to Rosetta Genomics nearly 20 years of legal and business experience in biotechnology and healthcare, with a particular emphasis on intellectual property, corporate development transactions, and employment law. Most recently she was Chief Operating Officer of Aptamir Therapeutics, a biotechnology start-up focused on the development of microRNA-based therapeutics for the treatment of obesity and other metabolic diseases. Previously she was General Counsel and Senior Vice President for Asuragen, Inc. and its spin-off, Mirna Therapeutics, where she managed a diverse portfolio of legal matters, including FDA, GMP, GLP, and CLIA compliance and regulations, intellectual property and litigation. Prior to that, Ms. Ward was general counsel of Ambion, where she oversaw the sale of Ambion to Applied Biosystems (now ThermoFisher Scientific) and spin-off of Asuragen. Prior to Ambion, Ms. Ward was Senior Intellectual Property Counsel with Yum! Brands and an Intellectual Property Associate in the Dallas office of Sidley Austin. Ms. Ward began her career as Intellectual Property Counsel for Applied Science Fiction in Austin, Texas.

"We are delighted to welcome Ana to the Rosetta Genomics team. Her legal and business experience are tailor-made for Rosetta, while her experience with microRNA diagnostics and therapeutics will be of great value as we continue to build Rosetta into a leading molecular diagnostics company focused on enabling truly personalized medicine," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

"I look forward to leveraging my business experience and legal expertise to benefit Rosetta Genomics as we continue to build and expand our high-value molecular testing services across a number of important medical specialties," said Ms. Ward. "Rosetta's broad and deep intellectual property portfolio offers multiple opportunities for monetization and partnership. I look forward to working with the Rosetta Genomics team to realize that potential."

Ms. Ward holds a BA in French and a MS in Molecular Biology and an MBA, all from the University of Texas, Austin, and a J.D. from the University of Texas Law School. Ms. Ward also holds an MS in Bioscience Regulatory Affairs from Johns Hopkins University. She is admitted to practice law in the State of Texas and is registered to practice before the U.S. Patent & Trademark Office.

#### **About Rosetta Genomics**

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development

and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company now offers core FISH, IHC and PCR-based testing capabilities and partnerships in Pathology, Oncology and Urology that provide additional content and platforms that complement Rosetta's microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company's Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively. For more information visit [www.rosettagx.com](http://www.rosettagx.com).

**Forward-Looking Statement Disclaimer**

Various statements in this release concerning Rosetta's future expectations, plans and prospects including, but not limited to statements relating to Rosetta Genomics expanding its testing menu, enabling personalized medicine, monetizing its intellectual property portfolio, entering into partnerships and having a leadership position in the diagnostics market constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

**Rosetta Genomics Contact:**  
Ken Berlin, President & CEO  
267.298.1159  
[investors@rosettagenomics.com](mailto:investors@rosettagenomics.com)

**Rosetta Genomics Investor Contact:**  
LHA  
Anne Marie Fields  
(212) 838-3777  
[afields@lhai.com](mailto:afields@lhai.com)

###